By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
The Most Well known Online Entertainment Forces to be reckoned with of 2023 - 2Mysterious bright blue cosmic blasts triggered by black holes shredding stars, scientists say. 'It's definitely not just an exploding star.'
- 3IDF continues counterterrorism operations in Gaza Strip, including destroying terror tunnels
- 4Satellite data reveals a huge solar storm in 2024 shrank Earth's protective plasma shield
- 5Discovering a sense of harmony: Individual Accounts of Reflection and Care
- Dominating Monetary Administration: A Bit by bit Manual for Making an Individual Financial plan
- The most effective method to Guarantee Scholastic Honesty in Web-based Degrees
- Scientists document a death from a meat allergy tied to certain ticks
- Extraordinary Shows to Long distance race on a Plane
- Cheetos and Doritos to launch new versions without artificial dyes
- How food assistance programs can feed families and nourish their dignity
- JFK's granddaughter reveals terminal cancer diagnosis, criticizes cousin RFK Jr.
- Haunting Giant Squid Surfaces in Japan and Devours Its Prey (Video)
- When faith comes under fire: How Iran’s repression of religious minorities has increased
